Enzychem Lifesciences Corporation Stock price

Equities

A183490

KR7183490002

Pharmaceuticals

End-of-day quote Korea S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
1,882 KRW -5.19% Intraday chart for Enzychem Lifesciences Corporation -3.93% +3.52%
Sales 2022 26.64B 19.77M Sales 2023 76.04B 56.42M Capitalization 155B 115M
Net income 2022 -25.09B -18.62M Net income 2023 -9.33B -6.92M EV / Sales 2022 -0.58 x
Net cash position 2022 155B 115M Net cash position 2023 132B 97.72M EV / Sales 2023 0.3 x
P/E ratio 2022
-5.24 x
P/E ratio 2023
-16.5 x
Employees 113
Yield 2022 *
-
Yield 2023
-
Free-Float 87.68%
More Fundamentals * Assessed data
Dynamic Chart
Enzychem Lifesciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Enzychem Lifesciences Announces Completion of Clinical Study Report for Phase 2 Study of EC-18 in Chemoradiation-Induced Oral Mucositis CI
Cadila Healthcare Limited Entered into A Definitive Agreement with Shilpa Medicare Limited and Enzychem Lifesciences CI
Hanmi Pharma to Manufacture COVID-19 Vaccine Developed by India's Zydus Cadila MT
Zydus Cadila Announces COVID-19 Vaccine Expansion Plan to Multiple Countries with Enzychem Lifesciences CI
Enzychem Lifesciences Corporation to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea CI
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot RE
Enzychem Lifesciences Files for FDA Breakthrough Therapy Designation for EC-18 for the Treatment of Chemoradiation-Induced Oral Mucositis CI
Enzychem Lifesciences Announces Positive Results for Phase 2 U.S. Study of EC-18 in Chemoradiation-Induced Oral Mucositis CI
Enzychem Lifesciences Announces Database Lock for Phase 2 Study of Ec-18 in Chemoradiation-Induced Oral Mucositis CI
Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program CI
Enzychem Lifesciences Announces Last Patient Enrolled in Stage 2 of Phase 2 Study of EC-18 in Chemoradiation Induced Oral Mucositis CI
Enzychem Lifesciences Corporation announced that it has received KRW 6.5006487 billion in funding CI
Enzychem Lifesciences Corporation announced that it has received KRW 23.5014976 billion in funding CI
Enzychem Lifesciences Corporation announced that it expects to receive KRW 6.5006487 billion in funding CI
More news
1 day-5.19%
1 week-3.93%
Current month+11.36%
1 month+13.99%
3 months+3.52%
6 months+25.05%
Current year+3.52%
More quotes
1 week
1 882.00
Extreme 1882
2 080.00
1 month
1 564.00
Extreme 1564
2 080.00
Current year
1 564.00
Extreme 1564
2 080.00
1 year
1 110.00
Extreme 1110
2 290.00
3 years
1 110.00
Extreme 1110
26 500.00
5 years
1 110.00
Extreme 1110
30 816.67
10 years
1 110.00
Extreme 1110
30 816.67
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 12-05-31
Chief Operating Officer 49 16-10-20
Director/Board Member 67 15-05-31
Members of the board TitleAgeSince
Chief Executive Officer 62 12-05-31
Director/Board Member 66 12-06-30
Director/Board Member 62 11-03-31
More insiders
Date Price Change Volume
24-03-28 1,882 -5.19% 707,277
24-03-27 1,985 -1.98% 645,341
24-03-26 2,025 -0.25% 584,035
24-03-25 2,030 +2.01% 736,697
24-03-22 1,990 +1.58% 720,796

End-of-day quote Korea S.E., March 27, 2024

More quotes
ENZYCHEM LIFESCIENCES CORPORATION is a Korea-based Company mainly engaged in the development and manufacture of medical raw materials. The Company provides D-cycloserine, a synthetic product utilizing chiral technology to treat tuberculosis; antibiotics, such as terizidone, cefbuperazone, cefazedone and others; magnetic resonance imaging (MRI) contrast agents such as gadoterate and gadopentate; others for antithrombotic drugs, antiinflammatory analgesic drugs, and drugs for gastric ulcer and hyperlipidemia. The Company also provides functional health food and finished drug products.
More about the company
  1. Stock
  2. Equities
  3. Stock Enzychem Lifesciences Corporation - Korea S.E.